HempFusion Wellness Inc (TSE:CBD.U) (OTCQX:CBDHF) (FRA:8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, announced Wednesday that it has submitted its dossier to the UK's Regulatory Food Safety Agency (FSA).
The company, in conjunction with its strategic and exclusive supply chain partner, said it submitted its novel foods application to the FSA with the coordination of a leading regulatory agency in Europe.
HempFusion said the submission represents the first step in the UK’s regulatory approval process required to allow products that contain CBD to be sold on the shelves of retailers.
READ: HempFusion Wellness CMO Ola Lessard becomes first two-term president of advocacy group US Hemp Roundtable
The submission includes a detailed analysis of the quality, stability, and safety of HempFusion's raw ingredients and many unique product formulations. In addition to proprietary heirloom hemp-sourcing and state-of-the-art low pressure and low-temperature C02 extraction methods, the submission also includes compliant labeling and testing requirements and complete toxicology data.
The company said its focus on compliance and sourcing premium raw materials further substantiates the quality of HempFusion's exclusive Organic Panoramic Hemp Extract and strategically positions HempFusion for continued sales within one of the largest markets in Europe, the UK. HempFusion believes the submission is an essential step in preparing for anticipated EU regulations.
"We believe the UK's decision to allow CBD companies to obtain a Novel Food Authorization from the FSA is a tremendous step forward for the global CBD industry," said CEO Jason Mitchell in a statement.
"HempFusion was built on the pillars of regulatory compliance. We have invested significant time, resources, and energy to ensure our products meet the highest standards, and we are pleased to report our submission includes completed toxicology data, which may represent one of the most complete submissions to date. We look forward to working with the FSA as regulations continue to evolve within the UK. This submission firmly establishes HempFusion as a future leader within the UK market.”
The novel food application's primary function is to assess CBD product safety, including detailed toxicology studies. HempFusion places significant importance on safety for its consumers as evidenced by its participation and co-sponsoring of many studies and clinical trials, such as the company’s participation in ValidCare’s liver and reproductive toxicity study -- believed to be the largest CBD human observational study to date.
The company has recently entered Europe through Ireland and looks forward to maintaining its long track record of compliance by meeting the requirements of the FSA, ahead of its broader planned expansion throughout the UK and the EU to further establish it as a global leader.
Contact the author: patrick@proactiveinvestors.com
Follow him on Twitter @PatrickMGraham